For the quarter ending 2025-09-30, NPCE made $27,354,000 in revenue. -$3,496,000 in net income. Net profit margin of -12.78%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 27,354,000 | 23,520,000 | 22,524,000 | 19,795,000 |
| Cost of goods sold | 6,186,000 | 5,388,000 | 5,182,000 | 5,029,500 |
| Gross profit | 21,168,000 | 18,132,000 | 17,342,000 | 14,765,500 |
| Selling, general and administrative | - | - | 15,049,000 | 14,447,500 |
| Sales and marketing | 12,598,000 | 12,043,000 | - | - |
| Research and development | 6,576,000 | 6,845,000 | 7,440,000 | 5,917,000 |
| General and administrative | 4,594,000 | 6,068,000 | - | - |
| Total operating expenses | 23,768,000 | 24,956,000 | 22,489,000 | 20,364,500 |
| Loss from operations | -2,600,000 | -6,824,000 | -5,147,000 | -5,599,000 |
| Interest income | 667,000 | 718,000 | 793,000 | 754,000 |
| Interest expense | 1,645,000 | 2,059,000 | 2,153,000 | 2,225,000 |
| Other income (expense), net | 82,000 | -486,000 | -82,000 | -17,500 |
| Net loss and comprehensive loss | -3,496,000 | -8,651,000 | -6,589,000 | -7,087,500 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.11 | -0.26 | -0.21 | -0.24 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.11 | -0.26 | -0.21 | -0.24 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 33,134,606 | 32,863,031 | 31,480,911 | -14,585,763.5 |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 33,134,606 | 32,863,031 | 31,480,911 | -14,585,763.5 |
NeuroPace Inc (NPCE)
NeuroPace Inc (NPCE)